Advanced Accelerator Application (NASDAQ:AAAP) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research cut shares of Advanced Accelerator Application (NASDAQ:AAAP) from a buy rating to a hold rating in a research report sent to investors on Wednesday, November 22nd.

According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “

A number of other equities research analysts also recently commented on AAAP. JMP Securities upgraded Advanced Accelerator Application from a market perform rating to an outperform rating and set a $69.00 price objective for the company in a report on Thursday, July 27th. Canaccord Genuity set a $47.00 price objective on Advanced Accelerator Application and gave the company a buy rating in a report on Thursday, July 27th. J P Morgan Chase & Co downgraded Advanced Accelerator Application from an overweight rating to a neutral rating and set a $82.00 price objective for the company. in a report on Monday, November 20th. BidaskClub upgraded Advanced Accelerator Application from a hold rating to a buy rating in a report on Thursday, August 3rd. Finally, Jefferies Group reissued a buy rating and issued a $60.00 target price (up from $50.00) on shares of Advanced Accelerator Application in a research note on Friday, September 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Advanced Accelerator Application has an average rating of Buy and an average target price of $69.80.

Shares of Advanced Accelerator Application (NASDAQ AAAP) opened at $81.27 on Wednesday. Advanced Accelerator Application has a 52-week low of $23.50 and a 52-week high of $81.75.

A number of large investors have recently bought and sold shares of the business. Advisor Group Inc. boosted its position in shares of Advanced Accelerator Application by 123.7% during the third quarter. Advisor Group Inc. now owns 1,528 shares of the company’s stock worth $103,000 after buying an additional 845 shares during the period. Quantbot Technologies LP acquired a new position in shares of Advanced Accelerator Application during the third quarter worth about $204,000. Empirical Finance LLC acquired a new position in shares of Advanced Accelerator Application during the third quarter worth about $265,000. JPMorgan Chase & Co. acquired a new position in shares of Advanced Accelerator Application during the first quarter worth about $160,000. Finally, Wells Fargo & Company MN boosted its position in shares of Advanced Accelerator Application by 81.5% during the second quarter. Wells Fargo & Company MN now owns 4,514 shares of the company’s stock worth $177,000 after buying an additional 2,027 shares during the period. 39.11% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/05/advanced-accelerator-applications-s-a-aaap-stock-rating-lowered-by-zacks-investment-research.html.

Advanced Accelerator Application Company Profile

Advanced Accelerator Applications SA is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.

Get a free copy of the Zacks research report on Advanced Accelerator Application (AAAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advanced Accelerator Application SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Application SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply